Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures... Show more
NNCSF moved above its 50-day moving average on September 29, 2025 date and that indicates a change from a downward trend to an upward trend. In of 21 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 29, 2025. You may want to consider a long position or call options on NNCSF as a result. In of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NNCSF just turned positive on September 30, 2025. Looking at past instances where NNCSF's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
NNCSF broke above its upper Bollinger Band on September 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NNCSF entered a downward trend on October 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NNCSF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.481) is normal, around the industry mean (10.722). P/E Ratio (66.910) is within average values for comparable stocks, (53.854). NNCSF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.737). NNCSF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (6.954) is also within normal values, averaging (14.072).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNCSF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Industry PharmaceuticalsOther
A.I.dvisor tells us that NNCSF and ASAPF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NNCSF and ASAPF's prices will move in lockstep.
Ticker / NAME | Correlation To NNCSF | 1D Price Change % | ||
---|---|---|---|---|
NNCSF | 100% | N/A | ||
ASAPF - NNCSF | 21% Poorly correlated | -5.50% | ||
NHNKY - NNCSF | 8% Poorly correlated | +0.81% | ||
NHNKF - NNCSF | 0% Poorly correlated | N/A | ||
NVYTF - NNCSF | 0% Poorly correlated | N/A | ||
MRCHF - NNCSF | 0% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To NNCSF | 1D Price Change % |
---|---|---|
NNCSF | 100% | N/A |
Pharmaceuticals category (385 stocks) | 2% Poorly correlated | -0.17% |
Pharmaceuticals: Other category (103 stocks) | 1% Poorly correlated | -0.26% |